Observation On Effects Of Amifostine Plus PC Chemotherapy Scheme In Advanced NSCLC Patients Treated With Chemotherapy

Background and ObjectiveLung Cancer is a common malignat tumour. Most of the lung cancer belongs to NSCLC, which are often reached an advanced stage when they are found. Chmotherapy is the main method for the treatment of the advanced lung cancer at present. But the chemotherapeutics are lethal to tumor cell and normal cell. So the untoward effect and dose-limiting toxicity usually imposed restrictions on the sufficiency of using chemotherapeutics. But clinical practice of the cell protector solved the above problem effectively. Amifostine is a kind of cell protector, which are mostly studied recently. Because of this, the Amifostine are widely applied in the chemotheray at home and abroad, which can reduce the toxicity during the chemotherapy. The PC (PTX/CBP) scheme is one of the most commonly used method during the advanced chemotherapy NSCLC. However the untoward effect of the PC scheme can not be ingnored. In view of less clinical report in the domestic and abroad documents about that the amifostine could lighten the relevant toxicity caused by the chemotherapy, so this study will apply to use Amifostine together with PC scheme into the treatment of the advanced lung cancer and observe the effect of the amifostine during the chemotherapy. MethodsSelecting 96 cases of the patient of the advanced NSCLC, who was treated during the period from July,2008 to September,2010, they will be grouped randomly into the group only PC scheme and the group amifostine plus PC scheme. A cyle is 21 days. After 4 cycles, the curative effect and the adverse reaction of this scheme will be evaluated according to the evaluation criterior of the RECIST made by WHO and the grading stardard of the anticarcinogen's acrute and subacute adverse reactions.ResultsEffect:CR 2 case, PR 16 cases, SD 27 cases, PD 3 cases of the group only PC scheme. And the effetive rate (CR+PR) was 37.5%. CR 2 case, PR 17 cases, SD 26 cases, PD 3 cases of the group amifostine plus PC scheme. And the effetive rate (CR+ PR) was 39.6%. There was no significant difference in the rate of the effect.The related chemotherapy toxicity of two groups:The hematological toxicity showed significant difference; The hepatotoxicity, neurotoxicity, alopecia and sore muscle showed significant statistical sense; The nausea showed no significant statistical sense. And there was no adverse event of concurrent serious anaphylaxis and infection, etc.ConclusionsAmifostine will not affect the short-term curative effect of the PC scheme for the lung cancer. And moreover, it can lighten the toxicity of PC, which can help the patient to improve the life quality. Of course, the random clinical study need to be processed further.